PharVision Advisers’s UiPath PATH Stock Holding History

PharVision Advisers’s Portfolio PATH Stock Details PATH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-15,122	Closed	-$194K	–	759
2025 Q2	$194K	Buy	+15,122	New	+$181K	0.28%	208

Other funds holding PATH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TAM

TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Mirae Asset Global ETFs Holdings Causeway Bay, Hong Kong $73.7B AUM 53.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PharVision Advisers's PATH Position: Q3 2025 in Review

PharVision Advisers sold out of UiPath (PATH) in Q3 2025, closing a stake of 15,122 shares — an estimated $194K sold.

PharVision Advisers first reported a position in PATH in Q2 2025 and held it in 1 quarter. The position peaked at $194K in Q2 2025. 473 funds tracked by Wall St. Rank hold PATH as of Q3 2025.

PharVision Advisers reported no remaining UiPath position as of Q3 2025 after selling out during the quarter.
PharVision Advisers sold 15,122 UiPath shares in Q3 2025, an estimated $194K.
PharVision Advisers first reported a position in UiPath in Q2 2025 and held it in 1 quarter.
PharVision Advisers's UiPath position peaked at $194K in Q2 2025.
473 funds tracked by Wall St. Rank held UiPath as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.